BACKGROUND: World Health Organization guidelines recommend screening with human papillomavirus (HPV) testing followed by either treatment of all HPV-positives, or by visual inspection (VIA) for triage to treatment, citing insufficient evidence to recommend either strategy over the other. METHODS: We assessed VIA and HPV testing individually, in combination (HPV-VIA cotesting), and as triage models. Three thousand women were screened in Inner Mongolia, China, concurrently with HPV testing and VIA in a real population setting. Screen-positive women underwent colposcopy, and biopsy, if indicated. Accuracy of screening algorithms for cervical intraepithelial neoplasia grade 2 or higher (CIN-2+) was calculated after controlling for verification bias. HPV testing followed by VIA triage for CIN-2+ detection was compared with Hybrid Capture 2 viral loads triage, measured in relative light units/cutoff. RESULTS: CIN-2+ prevalence was 1.0%. Corrected sensitivity, false negative rate, and specificity for CIN-2+, respectively, for primary HPV testing were 89.7%, 10.3%, and 83.3%; 44.8%, 55.2%, and 92·3% for VIA; 93.1%, 6.9%, and 80.2% for HPV-VIA cotesting; and 41.4%, 58.6, and 95.4% for HPV with VIA triage scenarios. Using relative light units/cutoff of 5 or greater to triage HPV-positive women had twice the sensitivity as VIA triage, with comparable specificity for CIN-2+. CONCLUSIONS: When VIA performs relatively poorly and HPV testing is available, adding VIA to sequential (ie, HPV followed by VIA triage) or primary (HPV-VIA cotesting) screening does not significantly improve CIN-2+ detection beyond primary HPV screening alone. Sequential screening (ie, HPV followed by VIA triage) reduces sensitivity too low for population-based screening programs. The HPV viral loads could offer an alternative low-resource country triage strategy.
BACKGROUND: World Health Organization guidelines recommend screening with human papillomavirus (HPV) testing followed by either treatment of all HPV-positives, or by visual inspection (VIA) for triage to treatment, citing insufficient evidence to recommend either strategy over the other. METHODS: We assessed VIA and HPV testing individually, in combination (HPV-VIA cotesting), and as triage models. Three thousand women were screened in Inner Mongolia, China, concurrently with HPV testing and VIA in a real population setting. Screen-positive women underwent colposcopy, and biopsy, if indicated. Accuracy of screening algorithms for cervical intraepithelial neoplasia grade 2 or higher (CIN-2+) was calculated after controlling for verification bias. HPV testing followed by VIA triage for CIN-2+ detection was compared with Hybrid Capture 2 viral loads triage, measured in relative light units/cutoff. RESULTS:CIN-2+ prevalence was 1.0%. Corrected sensitivity, false negative rate, and specificity for CIN-2+, respectively, for primary HPV testing were 89.7%, 10.3%, and 83.3%; 44.8%, 55.2%, and 92·3% for VIA; 93.1%, 6.9%, and 80.2% for HPV-VIA cotesting; and 41.4%, 58.6, and 95.4% for HPV with VIA triage scenarios. Using relative light units/cutoff of 5 or greater to triage HPV-positive women had twice the sensitivity as VIA triage, with comparable specificity for CIN-2+. CONCLUSIONS: When VIA performs relatively poorly and HPV testing is available, adding VIA to sequential (ie, HPV followed by VIA triage) or primary (HPV-VIA cotesting) screening does not significantly improve CIN-2+ detection beyond primary HPV screening alone. Sequential screening (ie, HPV followed by VIA triage) reduces sensitivity too low for population-based screening programs. The HPV viral loads could offer an alternative low-resource country triage strategy.
Authors: Neerja Bhatla; Kriti Puri; Alka Kriplani; Venkateswaran K Iyer; Sandeep R Mathur; Kalaivani Mani; Ravindra M Pandey Journal: Aust N Z J Obstet Gynaecol Date: 2012-01-25 Impact factor: 2.100
Authors: J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser Journal: Gynecol Oncol Date: 2001-11 Impact factor: 5.482
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Andrew Goldstein; Yang Lei; Lena Goldstein; Amelia Goldstein; Qiao Xu Bai; Juan Felix; Roberta Lipson; Maria Demarco; Mark Schiffman; Didem Egemen; Kanan T Desai; Sarah Bedell; Janet Gersten; Gail Goldstein; Karen O'Keefe; Casey O'Keefe; Tierney O'Keefe; Cathy Sebag; Lior Lobel; Anna Zhao; Yan Ling Lu Journal: Infect Agent Cancer Date: 2020-10-22 Impact factor: 2.965
Authors: Mohamed S Bangura; Yuqian Zhao; Maria Jose Gonzalez Mendez; Yixuan Wang; Salah Didier Sama; Kunpeng Xu; Ran Ren; Li Ma; You-Lin Qiao Journal: Front Med (Lausanne) Date: 2022-09-15
Authors: Pierre Vassilakos; Ania Wisniak; Rosa Catarino; Eveline Tincho Foguem; Christine Balli; Essia Saiji; Jean-Christophe Tille; Bruno Kenfack; Patrick Petignat Journal: Int J Gynecol Cancer Date: 2021-04-08 Impact factor: 3.437